Introduction to Tirzepatide
How a single peptide targeting two receptors became the most effective approved obesity and diabetes drug
The Drug That Changed the Ceiling
In May 2022, the FDA approved Mounjaro (tirzepatide) for Type 2 diabetes. In November 2023, it gained a second approval as Zepbound for chronic weight management. The molecule behind both brand names is tirzepatide, a first-in-class dual GIP/GLP-1 receptor agonist developed by Eli Lilly.
Before tirzepatide, the best obesity drugs produced roughly 15% mean body-weight loss. Tirzepatide pushed past 20% in the SURMOUNT-1 trial -- a result that closed the gap between pharmacotherapy and bariatric surgery. This unit explains what tirzepatide is, why it matters, and how dual agonism works at a high level.
what this course covers
What Is Tirzepatide
Tirzepatide is a 39-amino-acid synthetic peptide engineered to activate two incretin hormone receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1).
Unlike earlier drugs that targeted only GLP-1, tirzepatide was designed from scratch as a dual agonist. Its peptide backbone is based on the native GIP sequence, with modifications that give it meaningful GLP-1 receptor activity as well. A C20 fatty diacid side chain anchors it to serum albumin, extending its half-life to roughly 5 days and enabling once-weekly dosing.
The result is a single injection that engages two complementary metabolic pathways: GIP signaling for fat metabolism, beta-cell function, and energy balance, plus GLP-1 signaling for appetite suppression, gastric emptying, and glucose-dependent insulin secretion.
Why Tirzepatide Matters
Tirzepatide did not just add a percentage point to weight-loss benchmarks. It rewrote the assumptions about what a drug could achieve.
for diabetes: in the SURPASS trial program, tirzepatide produced HbA1c reductions of up to 2.6 percentage points, outperforming semaglutide 1mg head-to-head in SURPASS-2. many participants reached an HbA1c below 5.7% -- below the threshold for prediabetes.
for obesity: SURMOUNT-1 showed mean weight loss of 22.5% at the highest dose (15mg) over 72 weeks. more than a third of participants on the top dose lost 25% or more of their body weight. these numbers were in the range previously seen only with gastric sleeve surgery.
for the field: tirzepatide proved that adding a second receptor target to GLP-1 agonism could meaningfully increase efficacy. that insight opened the door to triple agonists like retatrutide and a wave of next-generation multi-receptor drugs now in development.
How Dual Agonism Works
A high-level look at the two-receptor mechanism before diving deeper in later units.
each receptor contributes something different to the overall metabolic effect:
GIP receptor: glucose-dependent insulinotropic polypeptide receptor. enhances beta-cell insulin secretion, improves fat metabolism and lipid storage in adipose tissue, and may contribute to central appetite regulation. tirzepatide has high potency at GIPR -- roughly 5x the activity of native GIP.
GLP-1 receptor: glucagon-like peptide-1 receptor. suppresses appetite via hypothalamic signaling, delays gastric emptying, stimulates glucose-dependent insulin secretion, and inhibits glucagon release. tirzepatide activates GLP-1R with lower relative potency compared to selective GLP-1 agonists like semaglutide, but the combined dual signaling produces greater overall weight loss.
What's Ahead
This is unit 1 of a mastery course with 11 content units plus a final exam, covering every angle of tirzepatide, from molecular engineering to clinical outcomes to the regulatory landscape.
in the units ahead, you'll study the 39-amino-acid sequence and the C20 fatty diacid that give tirzepatide its ~5-day half-life, then break down each receptor pathway -- GIP for beta-cell and adipose biology, GLP-1 for appetite and gastric emptying, and the biased dual-agonism that makes two targets better than one.
you'll then dig into the clinical evidence: the SURPASS program for type 2 diabetes (including the head-to-head beating of semaglutide in SURPASS-2), and the SURMOUNT program for obesity (SURMOUNT-1's 20%+ weight loss, SURMOUNT-4's discontinuation data, and the SURMOUNT-OSA first-ever sleep apnea approval). safety, dosing and reconstitution, the compounding controversy, and the next-gen pipeline (retatrutide, cagrisema) all get their own units.
every claim traces back to a primary source, and every limit of the evidence is stated explicitly. this course is designed to let you evaluate tirzepatide critically -- not to promote it.
Knowledge Check
Test what you've learned about tirzepatide and the dual agonist concept.
Practice Exercises
Reinforce your understanding with interactive exercises.